WO2023187622 - EDTA FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER PULMONARY DISEASES AND DISORDERS
National phase entry is expected:
Publication Number
WO/2023/187622
Publication Date
05.10.2023
International Application No.
PCT/IB2023/053034
International Filing Date
27.03.2023
Title **
[English]
EDTA FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER PULMONARY DISEASES AND DISORDERS
[French]
EDTA POUR LE TRAITEMENT DE LA FIBROSE KYSTIQUE ET D'AUTRES MALADIES ET TROUBLES PULMONAIRES
Applicants **
STERILECARE INC.
Inventors
MUELLER, Karen
Priority Data
63/324,332
28.03.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2531 | |
| EPO | Filing, Examination, Granting | 17978 | |
| Japan | Filing, Examination, Granting | 2525 | |
| South Korea | Filing, Examination, Granting | 2934 | |
| USA | Filing, Examination, Granting | 7940 |
Total:
33,908
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Compositions, solutions, products, devices, and methods related to EDTA, and uses thereof in treating pulmonary diseases and disorders such as cystic fibrosis are disclosed. Also disclosed are an inhalation device and an EDTA composition for dispensing via the inhalation device.[French]
L'invention concerne des compositions, des solutions, des produits, des dispositifs et des procédés associés à l'EDTA, et leurs utilisations dans le traitement de maladies et de troubles pulmonaires tels que la fibrose kystique. L'invention concerne également un dispositif d'inhalation et une composition d'EDTA pour la distribution par l'intermédiaire du dispositif d'inhalation.